论文部分内容阅读
目的探讨钙尔奇D联合阿仑膦酸钠在老年糖尿病骨质疏松症治疗中的临床价值。方法选取2014年3月~2015年9月我院收治的老年糖尿病骨质疏松症患者78例为研究对象,随机分为观察组与对照组,每组39例,两组患者均给予饮食与运动指导,并通过药物控制血糖,对照组加用钙尔奇D,观察组在对照组基础上联合阿仑膦酸钠,观察两组患者骨密度及骨转换指标变化。结果治疗前两组患者骨密度及骨转换指标无显著差异(P>0.05),治疗后均有改善,观察组治疗后股骨颈、腰椎L2~4、Ward三角区骨密度均明显高于对照组,差异有统计学意义(P<0.05);观察组治疗后BGP,BALP明显高于对照组,TP1NP显著低于对照组,差异有统计学意义(P<0.05)。结论在老年糖尿病骨质疏松治疗中联合应用钙尔奇D与阿仑膦酸钠,可显著提高骨密度,防止骨量丢失,值得推广。
Objective To investigate the clinical value of Calcium D combined with alendronate in the treatment of senile diabetic osteoporosis. Methods From March 2014 to September 2015, 78 elderly patients with diabetes mellitus and osteoporosis admitted to our hospital from March 2014 to September 2015 were randomly divided into observation group and control group, 39 cases in each group. Both groups were given diet and exercise Guided by the drug and control of blood glucose, the control group plus Galci D, the observation group on the basis of the control group combined with alendronate sodium, bone mineral density and bone turnover indicators were observed in two groups. Results There was no significant difference in bone mineral density and bone turnover between the two groups before treatment (P> 0.05), after treatment, the BMD of L2-4 and Ward triangle in the femoral neck and lumbar spine were significantly higher in the observation group than in the control group (P <0.05). The levels of BGP and BALP in the observation group were significantly higher than those in the control group, and TP1NP was significantly lower than that in the control group (P <0.05). Conclusions The combination of calcitonin D and alendronate sodium in the treatment of senile diabetic osteoporosis can significantly increase the bone density and prevent the loss of bone mass, which is worth to be popularized.